PSUR Repository Becomes Mandatory in EU
Mandatory use of the periodic safety update report repository becomes mandatory on June 13.
The European Union’s (EU) PSUR repository becomes mandatory on June 13, 2016. The single, central platform for submitting periodic safety update reports (PSUR) was developed by the European Medicines Agency (EMA) in collaboration with EU member states. Marketing authorization holders are now required to use the repository as a single point for all submissions. PSURs should no longer be submitted to national competent authorities (NCAs).
According to EMA, PSURs must be submitted following a drug’s authorization. They provide evaluation of the benefit-risk balance of a drug and results of studies performed on the medication. PSURs will now be sent to a single recipient, which simplifies the process. The repository also ensures that NCAs and EMA each have secure and timely access to information.
The PSUR repository, which must be used by regulatory authorities and pharmaceutical companies in the EU, was introduced by EU pharmacovigilance legislation to facilitate the exchange of safety information. Guidance and training are available on the EMA eSubmission website.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
